At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 203 enrolled
Drug / intervention
edoxaban +2 moredrug
Likely dose
Clopidogrel 75mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Parallel-Group, Multi-Center Study Of Adding Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention
In Brief
A Phase 2 clinical trial evaluating edoxaban, Clopidogrel, and 1 other intervention for Peripheral Arterial Disease. Completed, enrolled 203 participants across 42 sites in 7 countries.
Detailed Summary
This study is a randomized, open-label, blinded endpoint, parallel-group, active-control, multi-center, proof-of-concept study in subjects with Peripheral Arterial Disease (PAD), designed to assess the safety and potential efficacy of adding edoxaban to aspirin following femoropopliteal endovascular intervention, with or without stent placement, relative to current treatment practice with clopidogrel and aspirin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Arterial Disease
CountriesAustria, Belgium, Germany, Israel, Netherlands, Switzerland, United States
CollaboratorsUMC Utrecht
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2013
First PostedMar 2013
Primary CompletionDec 2014
TodayJul 2026
First PostedMar 1, 2013
Enrollment StartFeb 6, 2013
Primary CompletionDec 3, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.3 years ago
Interventions
edoxabandrug
Clopidogreldrug
75mg tablet
Aspirindrug